Puma Other Liab vs Total Assets Analysis
PBYI Stock | USD 2.94 0.08 2.65% |
Puma Biotechnology financial indicator trend analysis is much more than just breaking down Puma Biotechnology prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Puma Biotechnology is a good investment. Please check the relationship between Puma Biotechnology Other Liab and its Total Assets accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.
Other Liab vs Total Assets
Other Liab vs Total Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Puma Biotechnology Other Liab account and Total Assets. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Puma Biotechnology's Other Liab and Total Assets is 0.5. Overlapping area represents the amount of variation of Other Liab that can explain the historical movement of Total Assets in the same time period over historical financial statements of Puma Biotechnology, assuming nothing else is changed. The correlation between historical values of Puma Biotechnology's Other Liab and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Liab of Puma Biotechnology are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Other Liab i.e., Puma Biotechnology's Other Liab and Total Assets go up and down completely randomly.
Correlation Coefficient | 0.5 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Other Liab
Total Assets
Total assets refers to the total amount of Puma Biotechnology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Puma Biotechnology books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Most indicators from Puma Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Puma Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.As of now, Puma Biotechnology's Issuance Of Capital Stock is increasing as compared to previous years. The Puma Biotechnology's current Enterprise Value Over EBITDA is estimated to increase to 5.10, while Selling General Administrative is projected to decrease to under 65.7 M.
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 10.6M | 8.9M | 10.2M | 9.1M | Interest Income | 160K | 813K | 2.4M | 1.5M |
Puma Biotechnology fundamental ratios Correlations
Click cells to compare fundamentals
Puma Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Puma Biotechnology fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 234.9M | 244.2M | 226.6M | 222.1M | 230.5M | 165.1M | |
Total Stockholder Equity | 17.5M | (6M) | (2.4M) | 21.6M | 53.4M | 63.0M | |
Net Debt | 60.2M | 35.7M | 53.5M | 38.1M | 26.9M | 28.3M | |
Cash | 60M | 85.3M | 63.1M | 76.2M | 84.6M | 68.5M | |
Cash And Short Term Investments | 60M | 85.3M | 63.1M | 76.2M | 95.9M | 71.9M | |
Common Stock Shares Outstanding | 38.8M | 39.6M | 40.6M | 44.9M | 47.6M | 32.7M | |
Liabilities And Stockholders Equity | 234.9M | 244.2M | 226.6M | 222.1M | 230.5M | 165.1M | |
Other Stockholder Equity | 1.3B | 1.3B | 1.4B | 1.4B | 1.4B | 762.9M | |
Total Liab | 217.4M | 250.2M | 229.0M | 200.5M | 177.1M | 108.6M | |
Total Current Assets | 166.3M | 146.1M | 140.0M | 134.3M | 156.2M | 127.0M | |
Total Current Liabilities | 90.8M | 114.3M | 109.6M | 77.5M | 99.4M | 56.7M | |
Retained Earnings | (1.3B) | (1.3B) | (1.4B) | (1.4B) | (1.3B) | (1.3B) | |
Accounts Payable | 19.2M | 12.1M | 11.2M | 6.4M | 6.9M | 12.3M | |
Other Current Liab | 69.0M | 81.7M | 91.3M | 66.9M | 48.9M | 44.6M | |
Other Liab | 9M | 32.3M | 6.4M | 12.8M | 14.7M | 7.6M | |
Net Tangible Assets | (23.0M) | (80.1M) | (68.6M) | 21.6M | 19.4M | 18.5M | |
Property Plant And Equipment Net | 21.8M | 18.9M | 15.8M | 12.5M | 8.6M | 8.4M | |
Non Current Assets Total | 68.6M | 98.1M | 86.6M | 87.8M | 74.3M | 49.8M | |
Non Currrent Assets Other | 6.3M | 5.1M | 4.7M | 4.7M | 4.8M | 5.1M | |
Other Assets | 6.3M | 5.1M | 4.7M | 4.7M | 1.0 | 0.95 | |
Long Term Debt | 95.0M | 84.0M | 97.1M | 98.3M | 65.7M | 54.2M | |
Retained Earnings Total Equity | (1.3B) | (1.3B) | (1.4B) | (1.4B) | (1.2B) | (1.3B) | |
Short Term Investments | 51.6M | 8.1M | 19.0M | 4.9M | 11.4M | 10.8M | |
Non Current Liabilities Total | 126.6M | 135.9M | 119.4M | 123.0M | 77.7M | 68.1M | |
Capital Surpluse | 1.3B | 1.3B | 1.4B | 1.4B | 1.6B | 952.6M | |
Inventory | 3.2M | 3.5M | 7.1M | 4.5M | 7.1M | 8.2M | |
Other Current Assets | 2.7M | 23.8M | 18.3M | 8.3M | 4.7M | 8.4M | |
Deferred Long Term Liab | 5.8M | 868K | 955K | 743K | 854.5K | 811.7K | |
Property Plant And Equipment Gross | 21.8M | 18.9M | 22.6M | 1.1M | 16.3M | 8.7M | |
Accumulated Other Comprehensive Income | (12K) | 62K | 0.0 | (2K) | (4K) | (4.2K) | |
Intangible Assets | 40.5M | 74.1M | 66.1M | 70.6M | 60.9M | 34.3M | |
Property Plant Equipment | 3.3M | 2.5M | 15.8M | 1.1M | 1.3M | 1.3M | |
Net Receivables | 28.9M | 25.5M | 32.5M | 40.4M | 48.5M | 25.3M | |
Short Long Term Debt Total | 120.2M | 121.0M | 116.6M | 114.3M | 111.5M | 123.2M | |
Long Term Debt Total | 151.9M | 95.0M | 84.0M | 97.1M | 111.7M | 104.8M | |
Net Invested Capital | 112.4M | 92.4M | 94.6M | 119.9M | 153.1M | 135.2M | |
Net Working Capital | 75.5M | 31.9M | 30.4M | 56.8M | 56.8M | 49.8M |
Currently Active Assets on Macroaxis
When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.417 | Earnings Share 0.47 | Revenue Per Share 5.045 | Quarterly Revenue Growth 0.435 | Return On Assets 0.0973 |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.